BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

December 12, 2011 8:00 AM UTC

Affymax Inc. (NASDAQ:AFFY) gained $2.12 (36%) to $7.98 on Thursday after FDA's Oncologic Drugs Advisory Committee voted 15-1 with one abstention that peginesatide has a favorable benefit-risk profile to treat anemia in patients with chronic kidney disease who are on dialysis. The PDUFA date is March 27 (see Cover Story).

Affymax was up $2.39 (46%) to $7.64 on the week. Amgen Inc. (NASDAQ:AMGN), which markets the only ESAs approved in the U.S. for the CKD indication, rose $0.49 to $58.59...